BioSpace News Archive

Caris Life Sciences® announced that Virginia Commonwealth University Massey Cancer Center has joined Caris’ Precision Oncology Alliance™.

Theravance Biopharma, Inc. announced new ampreloxetine data in neurogenic orthostatic hypotension will be presented at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society, taking place November 2-5, 2022, in Maui, Hawaii.

Sinaptica today announced the publication of a Phase II trial conducted independently under the leadership of its co-founders, which yielded positive results demonstrating that precision-delivered noninvasive brain stimulation has the potential to slow the progression of cognitive and functional decline in patients with mild-to-moderate dementia due to Alzheimer’s disease.

COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management, a healthcare investment firm.

Actinium Pharmaceuticals, Inc. today highlighted multiple additions to its senior leadership team including Jenny Hsieh as Chief Strategy Officer, Sunitha Lakshminarayanan, as Senior Vice President, Head of CMC and Product Development, and Stephen Dressel as Vice President, Strategic Finance and Analysis.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its previously undisclosed development candidate, Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed by Chemo Research SL (“Chemo”) through its agent and affiliate Xiromed LLC (“Xiromed”), has received a U.S. Food and Drug Administration (“FDA”) Generic Drug User Fee Act (“GDUFA”) date of April 28, 2023.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results prior to market open on Tuesday, November 1, 2022.

NuVasive, Inc. announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close.

Can-Fite BioPharma Ltd. announced today that a poster entitled “Complete Response Induced by Namodenoson, an A3 Adenosine Receptor Agonist, in a Patient with Advanced Hepatocellular Carcinoma”

AVROBIO, Inc today announced that the sixth and final patient has been dosed in the collaborator-sponsored, Phase 1/2 clinical trial of an investigational gene therapy for the treatment of cystinosis.